Brain health software group Cambridge Cognition Holdings plc (AIM: COG) on Wednesday congratulated Bristol Myers Squibb for the recent FDA approval of Cobenfy (KarXT), a novel drug for schizophrenia, and for the positive results published in The American Journal of Psychiatry.

The publication showcased the use of Cambridge Cognition's CANTAB product in two Phase 3 trials of Cobenfy, which targets the M1 and M4 muscarinic receptors, offering a more effective treatment for both positive and negative schizophrenia symptoms compared to traditional antipsychotics.

CANTAB's digital assessments were integral in these trials, providing accurate and objective measures of cognitive function, which were crucial for the post-hoc analysis conducted by Bristol Myers Squibb. This analysis demonstrated improvements in cognitive performance in patients with pre-specified cognitive impairments after treatment with Cobenfy. The results underscore CANTAB's value in advancing the development of schizophrenia treatments.

Cambridge Cognition remains committed to supporting pharmaceutical companies with its cutting-edge digital tools. The company's CANTAB assessments and eCOA platform enhance clinical trial outcomes, early patient identification and overall research efficiency.